Abstract: [Problem] To provide a biomarker for predicting the therapeutic efficacy of allergen immunotherapy.

Abstract: A living body state monitor apparatus includes: a living body information acquisition device to acquire living body information containing an electrocardiography waveform and a pulse waveform from a user; an irregular heartbeat detection section to detect an irregular heartbeat from the electrocardiography waveform; and a pulse wave feature quantity extraction section to extract a pulse wave feature quantity from a pulse wave corresponding to the irregular heartbeat. Further, a living body state determination section is included to determine a danger degree on user's living body state using both of (A) information on kind and/or continued time period of an irregular heartbeat detected by the irregular heartbeat detection section, and (B) a pulse wave feature quantity extracted by the pulse wave feature quantity extraction section, and/or a variation of the extracted pulse wave feature quantity.

Abstract: An heart rhythm monitoring device for a vehicle, which determines whether a driver has an arrhythmia includes a vehicle state determining portion that determines whether the vehicle is stopped; an electrode arranged on a steering wheel in a position where the driver grips the steering wheel; an electrocardiogram waveform obtaining portion that obtains a first electrocardiogram waveform from the electrode; and a signal processing and calculating portion that determines whether the heart rhythm of the driver is erratic based on the first electrocardiogram waveform. When the vehicle is in motion, the signal processing and calculating portion determines whether the heart rhythm of the driver is erratic based on the waveform component that is strong with respect to noise in the first electrocardiogram waveform.

Abstract: It is an object of the present invention to provide a simple, reliable and low-invasive method to detect perilymph fistulas. The present invention provides a method for detecting a perilymph fistula, which comprises detecting the existence of Cochlin in body fluid existing in the middle ear.

Abstract: The invention provides a surgical device for endoscopic surgery having the function of temporarily storing liquid (a first function), the function of keeping a physical space for surgery and a sufficient endoscopic field (a second function), and the function of protecting organs (a third function), and an insertion device for inserting the surgical device into a body. [Solving Means] The surgical device for endoscopic surgery is an inter-organ spacer (10) including liquid holding means (1) formed of a porous soft material having the ability to temporarily store liquid and the ability to retain its shape. The insertion device for inserting the inter-organ spacer into a body includes a tubular holder capable of holding the inter-organ spacer for endoscopic surgery.

Abstract: A biological condition evaluation apparatus determines a symptom of a heart abnormality based on at least one index calculated from a heartbeat interval and/or a pulse interval. The apparatus determines whether it is in a referential period where an amount of change in the index is comparatively small. The apparatus determines whether a plurality of conditions are satisfied or not in an evaluation period set after the referential period. One condition is that an amount of change in the index in the evaluation period is greater than that observed during the referential period. Another condition is that a rate of change in the index is equal to or greater than a predetermined threshold value. The apparatus determines that there is a symptom of a heart abnormality, when both the conditions are satisfied.

Abstract: A new mutant gene related to the onset of CMPD, particularly, the new mutant gene related to the onset of CMPD in patients who develop CMPD despite of JAK2V617F-negative, and an evaluation method for evaluating CMPD are provided. By detecting the following mutation in a JAK2 gene or an EPOR gene in a biological sample of human origin, the possibility of CMPD is evaluated. (a) a mutation from G at the 2116th position to A in a base sequence of SEQ ID NO: 1, (b) a deletion of a nucleotide residue from the 2121st to 2126th position in a base sequence of SEQ ID NO: 1, (c) a mutation from C at the 1641st position to G in a base sequence of SEQ ID NO: 4.

Abstract: A novel therapeutic agent for amyotrophic lateral sclerosis. A therapeutic agent for amyotrophic lateral sclerosis, including a compound having xanthine dehydrogenase inhibitory action and not acting as a substrate for the purine salvage pathway.

Abstract: The present invention provides a protein having a potent cell-death inducing activity that is, a fused protein is in which a modified Bax protein fused with GFP at the N-terminus and is further fused with a homing signal peptide having a homing activity specific for endothelial cells in tumor angiogenesis; a gene coding the fused protein; and a cancer cell growth inhibitor containing the fused protein. Namely, a fused gene containing a cell death-inducing gene acting specially on cancer tissue, which is a fused gene having a gene encoding a homing signal peptide sequence specific for endothelial cells undergoing angiogenesis, a gene encoding a green fluorescent protein (GFP) and a gene encoding ?NBax protein, which is human Bax with a deletion of the N-terminal sequence containing the BH3 domain in this order, and a fusion protein encoded by the fused gene.